C677T methylene-tetrahydrofolate reductase mutation in type 2 diabetic patients with and without hyperhomocysteinaemia (Q45138816)

9 December 2017

title

C677T methylene-tetrahydrofolate reductase mutation in type 2 diabetic patients with and without hyperhomocysteinaemia (English)

1 reference

9 December 2017

Buysschaert M

1

1 reference

9 December 2017

Gala JL

series ordinal

2

1 reference

9 December 2017

Bessomo A

series ordinal

3

1 reference

9 December 2017

Hermans MP

series ordinal

4

1 reference

9 December 2017

publication date

1 September 2004

1 reference

9 December 2017

published in

Diabetes and Metabolism

1 reference

9 December 2017

volume

30

1 reference

9 December 2017

issue

4

1 reference

9 December 2017

page(s)

349-354

1 reference

A quantitative assessment of plasma homocysteine as a risk factor for vascular disease. Probable benefits of increasing folic acid intakes

9 December 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2807%2970127-1

7 January 2021

Hyperhomocysteinemia following a methionine load in patients with non-insulin-dependent diabetes mellitus and macrovascular disease

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2807%2970127-1

7 January 2021

Plasma homocysteine levels and mortality in patients with coronary artery disease

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2807%2970127-1

7 January 2021

Hyperhomocysteinemia is associated with an increased risk of cardiovascular disease, especially in non-insulin-dependent diabetes mellitus: a population-based study

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2807%2970127-1

7 January 2021

Fasting and post-methionine homocysteine levels in NIDDM. Determinants and correlations with retinopathy, albuminuria, and cardiovascular disease.

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2807%2970127-1

7 January 2021

Hyperhomocysteinemia is a risk factor for coronary arteriosclerosis in Japanese patients with type 2 diabetes

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2807%2970127-1

7 January 2021

Hyperhomocysteinemia increases risk of death, especially in type 2 diabetes : 5-year follow-up of the Hoorn Study.

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2807%2970127-1

7 January 2021

Hyperhomocysteinemia in type 2 diabetes: relationship to macroangiopathy, nephropathy, and insulin resistance.

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2807%2970127-1

7 January 2021

Plasma homocysteine and risk for congestive heart failure in adults without prior myocardial infarction

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2807%2970127-1

7 January 2021

Hyperhomocysteinaemia is associated with coronary events in type 2 diabetes

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2807%2970127-1

7 January 2021

Hyperhomocysteinemia and its role in the development of atherosclerosis

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2807%2970127-1

7 January 2021

Homocysteine and atherothrombosis

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2807%2970127-1

7 January 2021

A candidate genetic risk factor for vascular disease: a common mutation in methylenetetrahydrofolate reductase

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2807%2970127-1

7 January 2021

Mutation (677 C to T) in the methylenetetrahydrofolate reductase gene aggravates hyperhomocysteinemia in hemodialysis patients.

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2807%2970127-1

7 January 2021

Hyperhomocyst(e)inemia as a risk factor for occlusive vascular disease

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2807%2970127-1

7 January 2021

Comparison of tests of beta-cell function across a range of glucose tolerance from normal to diabetes

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2807%2970127-1

7 January 2021

Poor metabolic control, early age at onset, and marginal folate deficiency are associated with increasing levels of plasma homocysteine in insulin-dependent diabetes mellitus. A five-year follow-up study

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2807%2970127-1

7 January 2021

Plasma total homocysteine and cysteine in relation to glomerular filtration rate in diabetes mellitus

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2807%2970127-1

7 January 2021

Lipid-lowering drugs and homocysteine

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2807%2970127-1

7 January 2021

Treatment of hyperhomocyst(e)inemia: physiological basis

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2807%2970127-1

7 January 2021

Elevated plasma homocysteine level is an independent predictor of coronary heart disease events in patients with type 2 diabetes mellitus

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2807%2970127-1

7 January 2021

DACH-LIGA homocystein (german, austrian and swiss homocysteine society): consensus paper on the rational clinical use of homocysteine, folic acid and B-vitamins in cardiovascular and thrombotic diseases: guidelines and recommendations

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2807%2970127-1

7 January 2021

Common methylenetetrahydrofolate reductase gene mutation leads to hyperhomocysteinemia but not to vascular disease: the result of a meta-analysis

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2807%2970127-1

7 January 2021

Genetic and nutritional factors contributing to hyperhomocysteinemia in young adults.

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2807%2970127-1

7 January 2021

C677T (thermolabile alanine/valine) polymorphism in methylenetetrahydrofolate reductase (MTHFR): its frequency and impact on plasma homocysteine concentration in different European populations

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2807%2970127-1

7 January 2021

Determinants and vitamin responsiveness of intermediate hyperhomocysteinemia (> or = 40 micromol/liter). The Hordaland Homocysteine Study

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2807%2970127-1

7 January 2021

Effect of the methylenetetrahydrofolate reductase 677C-->T mutation on the relations among folate intake and plasma folate and homocysteine concentrations in a general population sample

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2807%2970127-1

7 January 2021

Methylenetetrahydrofolate reductase polymorphism affects the change in homocysteine and folate concentrations resulting from low dose folic acid supplementation in women with unexplained recurrent miscarriages

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2807%2970127-1

7 January 2021

Prospective study of coronary heart disease incidence in relation to fasting total homocysteine, related genetic polymorphisms, and B vitamins: the Atherosclerosis Risk in Communities (ARIC) study.

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2807%2970127-1

7 January 2021

Plasma homocysteine, methylenetetrahydrofolate reductase gene polymorphism and carotid intima-media thickness in Italian type 2 diabetic patients

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2807%2970127-1

7 January 2021

Association of methylenetetrahydrofolate reductase gene polymorphism with carotid arterial wall thickening and myocardial infarction risk in NIDDM

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2807%2970127-1

7 January 2021

The association between end-stage diabetic nephropathy and methylenetetrahydrofolate reductase genotype with macroangiopathy in type 2 diabetes mellitus

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2807%2970127-1

7 January 2021

MTHFR 677C-->T polymorphism and risk of coronary heart disease: a meta-analysis.

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2807%2970127-1

7 January 2021

No association between MTHFR gene polymorphism and diabetic nephropathy in Japanese type II diabetic patients with proliferative diabetic retinopathy

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2807%2970127-1

7 January 2021

Effects of the C677T and A1298C polymorphisms of the MTHFR gene on the genetic predisposition for diabetic nephropathy

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2807%2970127-1

7 January 2021

MTHFR gene polymorphism as a risk factor for diabetic retinopathy in type 2 diabetic patients without serum creatinine elevation

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2807%2970127-1

7 January 2021

Methylenetetrahydrofolate reductase gene polymorphism, hyperhomocysteinemia and occlusive retinal vascular disease in type 2 diabetic and non-diabetic subjects.

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2807%2970127-1

7 January 2021

10.1016/S1262-3636(07)70127-1

Identifiers

DOI

1 reference

9 December 2017

1 reference